Uveitis refers to inflammation of the uveal tract, which includes the iris, ciliary body, and choroid—the middle layer of the eye. This inflammation can extend to nearby ocular structures such as the sclera, cornea, retina, optic nerve, and vitreous humor. Often driven by immune responses to infections, uveitis can result in severe complications. It is responsible for approximately 10–15% of global blindness cases, and over one-third of patients experience some form of vision deterioration. Uveitis affects individuals of all age brackets, with varying prevalence patterns based on age and geography. Anterior uveitis is the most commonly diagnosed subtype, accounting for nearly half of all cases, whereas posterior uveitis is comparatively rare.

👉 Discover how the Uveitis Market is evolving and get the latest insights into emerging therapies and market forecasts.

Epidemiological Insights: Uveitis in the 7MM (2020–2034)

Total diagnosed prevalent population

Subtype-specific prevalence data

Prevalence by anatomical classification

Cases categorized by etiology

Epidemiology Snapshot
As of 2022, uveitis impacted nearly 1 million individuals across the 7 major markets (7MM). The United States alone represented approximately 378,000 cases—about 37.5% of the total. Spain recorded the lowest figures, contributing just 7% of the 7MM burden. In the U.S., noninfectious uveitis (NIU) was substantially more common than infectious uveitis (IU), with 344,587 cases of NIU compared to 33,695 IU cases. Both types are projected to grow steadily in prevalence throughout the forecast timeline.

Market Landscape: Uveitis
The uveitis treatment market in the 7MM reached an estimated value of USD 1.4 billion in 2022.

Growth Drivers

Innovative treatments with novel mechanisms and more effective delivery methods are entering the market, offering improved clinical results.

Deeper insight into the pathogenesis of uveitis is enabling the development of targeted, mechanism-based therapies.

Ongoing Challenges

Many current therapies are associated with considerable side effects, limiting their long-term use.

The field still leans heavily on off-label drugs, and a lack of robust randomized clinical trials (RCTs) complicates efforts to establish standardized treatment guidelines.

Emerging Uveitis Therapies to Watch
Several novel agents are currently in clinical development or trial phases, including:

TRS01

Licaminlimab

Vamikibart

OLUMIANT

EYS606

Izokibep

Brepocitinib

OCS-01

Others are also advancing through the pipeline.

Top Companies Shaping the Uveitis Treatment Landscape
Leading players actively developing or marketing uveitis therapies include:

Tarsier Pharma

Oculis Pharma

Roche

Eleven Biotherapeutics

Eli Lilly and Company

Eyevensys

Acelyrin

Affibody Medical

Priovant Therapeutics

Among others.

📘 For comprehensive data and trends, access the complete Uveitis Market Report and stay ahead in this rapidly growing therapeutic space.